Clinical Trials
123
5 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
5
4.1%
Completed
93
75.6%
Recruiting
4
3.3%
Terminated
16
13.0%
Unknown
1
0.8%
Withdrawn
4
3.3%
No approval data available
- Six 30-second all-out sprints altered nearly one-quarter of 2,884 detected plasma proteins immediately after exercise, versus only seven proteins after 90 minutes of moderate cycling. - Sprint-interval exercise (SIE) changed more than 200 metabolites and preferentially regulated 32 of 33 proteins associated with lower risk of obesity, type 2 diabetes, and metabolic disorders. - Adipocytes exposed to post-sprint plasma showed widespread gene-expression changes (1,128 genes upregulated), indicating adipose tissue is a key target of intensity-dependent signaling. - The findings, published in Cell Reports Medicine, suggest exercise intensity strongly shapes interorgan crosstalk, though the small, mostly male cohort limits generalizability.
- A new perspective by João Pedro de Magalhães argues aging is not passive decay but the unwanted continuation of developmental programs that fail to switch off after growth and reproduction end. - The hyperfunction theory, rooted in Mikhail Blagosklonny's "quasi-programs," links evolutionary theory directly to the molecular mechanisms of aging. - Evidence such as rapamycin, reduced growth hormone/IGF-1 signaling, and caloric restriction extending lifespan fits a programmatic rather than purely damage-based model. - Partial cellular reprogramming is framed as a direct test of the theory, potentially enabling tissue-specific rejuvenation while avoiding side effects like cancer risk.
- Rockefeller University researchers discovered that the amino acid arginine is critical for MHC-1 protein production, a key immune system alarm signal. - Low arginine levels impair the immune system's ability to detect mutated cancer cells and virus-infected cells, allowing threats to escape detection. - In mouse models, arginine-rich diets reduced colon tumor development and led to milder symptoms from influenza and SARS-CoV-2 infections. - The findings, published in Cell, suggest inexpensive arginine supplementation could be tested alongside immunotherapies or in high-risk populations.
- Rockefeller University researchers have uncovered the atomic-level mechanism by which Mycobacterium tuberculosis develops resistance to rifampicin, the cornerstone TB drug for decades. - The team discovered that rifampicin resistance mutations slow down RNA polymerase, and a second mutation compensates—revealing slow transcription as a vulnerability that can be exploited. - Combining two drugs that hit different steps of transcription produced powerful synergy, effectively killing dormant TB bacteria hiding in lung granulomas. - The structural biology approach extends beyond TB to other pathogens including SARS-CoV-2 and Clostridium difficile, offering a blueprint for rational antibiotic combination design.
- Researchers at Rockefeller University have developed an engineered antibody that delivers the same therapeutic effect as IVIG at 100 times lower doses in preclinical studies. - The breakthrough builds on 40 years of research into Fc receptors and reveals a novel mechanism where FcγRIIB and DC-SIGN receptors bind together to enhance anti-inflammatory signaling. - The new molecule can be produced synthetically without human plasma, potentially addressing IVIG's supply shortages and enabling treatment of additional autoimmune diseases currently limited by dosing constraints.
- A modified CD40 agonist antibody called 2141-V11 demonstrated remarkable efficacy in a phase 1 clinical trial, with six of 12 patients experiencing significant tumor reduction and two achieving complete remission. - The drug showed systemic anti-tumor effects when injected directly into tumors, causing cancer disappearance at both injected and distant sites without the severe toxicities associated with previous CD40 therapies. - Tissue analysis revealed the formation of tertiary lymphoid structures within tumors, creating immune-rich microenvironments that replaced cancerous tissue with organized immune cell aggregates. - Nearly 200 patients are now enrolled in follow-up phase 1 and phase 2 trials investigating the drug's effectiveness against specific aggressive cancers including bladder cancer, prostate cancer, and glioblastoma.
- The HIV treatment pipeline for 2025 features innovative dual-drug combinations with extended dosing intervals ranging from weekly oral tablets to six-monthly injections, representing a significant shift toward treatment simplification. - Nine studies presented at Glasgow 2024 demonstrated promising results for nucleoside-sparing combinations using novel drug classes including capsid inhibitors, with companies like Gilead, MSD, and ViiV Healthcare leading development efforts. - Phase 2/3 trials are advancing multiple long-acting formulations, including lenacapavir-based combinations and ultra-long-acting versions of existing drugs, though challenges remain regarding cost-effectiveness against upcoming generic dolutegravir. - Weekly oral combinations such as islatravir plus lenacapavir are showing comparable efficacy to daily regimens in switch studies, while six-monthly options include both small molecules and broadly neutralizing antibodies.
• Researchers have identified a unique transcriptomic signature for fibrolamellar hepatocellular carcinoma (FLC), distinguishing it from other liver cancers. • A clinical trial has been initiated, combining DT2216 and irinotecan, showing promise in preliminary results against FLC. • The study highlights the importance of examining tumor margins for hidden FLC cells to prevent potential recurrence. • The research suggests defining cancer by its impact on protein activity balance rather than solely by DNA changes.
- Researchers at Emory University have identified a novel enzyme, CU43, that effectively reduces IgG-mediated pathologies in mouse models of autoimmune diseases. - The enzyme demonstrated remarkable potency, requiring 4,000 times less dosage than current treatments for myasthenia gravis to achieve similar symptom reduction. - This new enzyme could potentially offer fewer side effects and alternative administration options for patients with a range of autoimmune disorders. - The research team plans to expedite clinical trials in humans to explore the enzyme's therapeutic potential across various IgG-mediated pathologies.
